You’re doing a Q-bank block and the question feels “easy”… until you miss it because you didn’t respect the answer choices. Antiepileptic drugs (AEDs) are classic USMLE territory because they test mechanism, adverse effects, enzyme interactions, pregnancy, and which seizure types get worse. Let’s walk through a vignette the way Step wants you to: pick the best answer, then interrogate every distractor like it’s trying to trick you (because it is).
Clinical Vignette (USMLE-Style)
A 28-year-old woman with epilepsy is switched to a new medication after reporting worsening acne, weight gain, and irregular menses on her current regimen. Two months later, she presents with easy bruising and gum bleeding. She has also noticed increased facial hair. Vitals are normal. Exam shows mild gingival hypertrophy and scattered ecchymoses. CBC shows thrombocytopenia.
Which medication is most likely responsible?
- A. Carbamazepine
- B. Ethosuximide
- C. Levetiracetam
- D. Phenytoin
- E. Valproate
Step-by-Step: Identify the Correct Answer
Correct Answer: D. Phenytoin
This vignette is screaming phenytoin toxicity/adverse effects, and Step loves to bundle them:
Classic phenytoin adverse effects (high-yield list):
- Gingival hyperplasia
- Hirsutism
- Coarsened facial features
- Neurologic: nystagmus, ataxia, diplopia, sedation
- Hematologic: megaloblastic anemia (↓ folate), thrombocytopenia
- Bone: osteopenia (via vitamin D metabolism)
- Teratogenic: fetal hydantoin syndrome (craniofacial anomalies, hypoplastic nails/distal phalanges, growth restriction)
Mechanism (must know):
- Blocks voltage-gated Na⁺ channels → prolongs the inactivated state → ↓ high-frequency firing
- Used for focal seizures and generalized tonic-clonic seizures
Phenytoin kinetics (USMLE favorite):
- Saturable metabolism → zero-order kinetics at higher doses
- Narrow therapeutic index; lots of drug interactions
Why Every Other Answer Choice Is Wrong (and What They’re Trying to Teach)
A. Carbamazepine
Why it’s tempting: also a sodium-channel blocker; also causes blood problems.
Why it’s wrong here: carbamazepine does not classically cause gingival hyperplasia or hirsutism.
High-yield carbamazepine facts:
- Mechanism: blocks voltage-gated Na⁺ channels (like phenytoin)
- Uses:
- Focal seizures
- Generalized tonic-clonic seizures
- Trigeminal neuralgia (classic)
- Bipolar disorder (sometimes)
- Adverse effects:
- Agranulocytosis/aplastic anemia (watch CBC)
- Hepatotoxicity
- SIADH → hyponatremia
- Dizziness, diplopia
- Teratogenic: neural tube defects
- Drug interactions:
- Strong CYP450 inducer (lowers levels of many meds, including OCPs)
Exam pearl: If the stem emphasizes hyponatremia or trigeminal neuralgia, think carbamazepine/oxcarbazepine.
B. Ethosuximide
Why it’s tempting: AED adverse effects are testable and this one has a “catchphrase.”
Why it’s wrong here: ethosuximide is for absence seizures and doesn’t cause gingival hyperplasia/hirsutism.
High-yield ethosuximide facts:
- Use: absence seizures (3-Hz spike-and-wave)
- Mechanism: blocks T-type Ca²⁺ channels in thalamus
- Adverse effects (the famous triad + a big one):
- Ethosuximide causes EFGHIJ:
- Ethosuximide
- Fatigue
- GI distress
- Headache
- Itching (urticaria)
- Johnson syndrome (rare but important)
- Ethosuximide causes EFGHIJ:
Exam pearl: If a child is “staring into space” with 3-Hz spike-and-wave, ethosuximide is usually the cleanest answer.
C. Levetiracetam
Why it’s tempting: common modern AED; lots of questions test “well tolerated.”
Why it’s wrong here: levetiracetam is not associated with gingival hyperplasia, hirsutism, or classic metabolic/toxic patterns in this stem.
High-yield levetiracetam facts:
- Mechanism: binds SV2A (synaptic vesicle protein) → modulates neurotransmitter release (exact downstream effects not fully defined)
- Uses: broad spectrum—focal and generalized seizures; often chosen for fewer interactions
- Adverse effects:
- Behavioral changes: irritability, agitation, mood symptoms
- Somnolence, dizziness
Exam pearl: If the stem emphasizes psychiatric/behavioral side effects with an otherwise “clean” AED, levetiracetam is a common pick.
E. Valproate
Why it’s tempting: causes weight gain + menstrual issues; can cause thrombocytopenia; very testable.
Why it’s wrong here: the stem’s signature combination of gingival hyperplasia + hirsutism is much more phenytoin than valproate.
That said—valproate is still very high yield and worth knowing cold:
High-yield valproate facts:
- Mechanisms (multi-hit):
- ↑ GABA (inhibits GABA transaminase)
- Blocks Na⁺ channels
- Blocks T-type Ca²⁺ channels
- Uses:
- Broad spectrum: focal + generalized
- Absence seizures (alternative)
- Bipolar disorder
- Migraine prophylaxis (ties into “Headache & Sleep” systems content)
- Adverse effects:
- Hepatotoxicity (esp. kids)
- Pancreatitis
- Neural tube defects (major teratogen)
- Weight gain
- Tremor
- Thrombocytopenia
- Hyperammonemia (valproate-induced; can cause encephalopathy)
Exam pearl: If you see hyperammonemia with normal LFTs after valproate, think urea cycle disruption/mitochondrial toxicity → treat supportively and consider L-carnitine in severe cases (institution-dependent, but commonly tested conceptually).
Quick Comparison Table (High-Yield)
| Drug | Primary MOA | Classic Use | Signature Adverse Effects | Key Step Traps |
|---|---|---|---|---|
| Phenytoin | Blocks Na⁺ channels (prolongs inactivation) | Focal, tonic-clonic | Gingival hyperplasia, hirsutism, coarsened facies, nystagmus/ataxia, ↓ folate, osteopenia, teratogen | Zero-order kinetics, CYP inducer |
| Carbamazepine | Blocks Na⁺ channels | Focal, tonic-clonic, trigeminal neuralgia | Agranulocytosis, SIADH, teratogen | CYP inducer; hyponatremia clue |
| Ethosuximide | Blocks T-type Ca²⁺ | Absence | EFGHIJ, Stevens–Johnson | Only for absence (board-style simplification) |
| Levetiracetam | Binds SV2A | Broad | Behavior/mood changes, sedation | Minimal interactions—“clean” option |
| Valproate | ↑ GABA, blocks Na⁺ + T-type Ca²⁺ | Broad, migraine, bipolar | Hepatotoxicity, pancreatitis, NTDs, weight gain, hyperammonemia, thrombocytopenia | Avoid in pregnancy |
Micro–Q-Bank Mindset: How to Stop Missing These
When you see AED questions, force yourself to categorize the stem into one of these buckets:
-
Seizure type clue
- Absence → ethosuximide (or valproate)
- Focal/tonic-clonic → phenytoin/carbamazepine/levetiracetam (context matters)
-
Signature toxicity
- Gingival hyperplasia/hirsutism → phenytoin
- SIADH/hyponatremia → carbamazepine/oxcarbazepine
- EFGHIJ → ethosuximide
- Behavioral/mood → levetiracetam
- Hepatotox/pancreatitis/NTDs/hyperammonemia → valproate
-
Pregnancy + teratogenicity
- High-risk: valproate (NTDs), phenytoin (fetal hydantoin), carbamazepine (NTDs)
- “Safer-ish” common test vibe: levetiracetam (often preferred clinically; questions vary)
-
Drug interactions
- Inducers: phenytoin, carbamazepine (and phenobarbital—not in this question but commonly tested)
- Valproate tends to inhibit metabolism of some drugs (conceptually important)
Take-Home Summary (What You Should Remember on Test Day)
- Phenytoin: Na⁺ channel blocker with gingival hyperplasia + hirsutism + neuro toxicity; zero-order kinetics.
- Carbamazepine: Na⁺ channel blocker; SIADH + agranulocytosis; trigeminal neuralgia.
- Ethosuximide: absence seizures; T-type Ca²⁺; EFGHIJ.
- Levetiracetam: SV2A; behavioral changes; relatively few interactions.
- Valproate: broad; hepatotoxicity, pancreatitis, NTDs, hyperammonemia, thrombocytopenia, weight gain; also migraine prophylaxis.
Frequently Asked Questions
What antiepileptic drug causes gingival hyperplasia, hirsutism, and thrombocytopenia?
Phenytoin is the antiepileptic drug classically associated with gingival hyperplasia, hirsutism, and thrombocytopenia. This combination is a strong test clue, especially when paired with coarsened facial features or neurologic toxicity such as nystagmus, ataxia, diplopia, or sedation. Phenytoin can also cause megaloblastic anemia from decreased folate and osteopenia through altered vitamin D metabolism.
How do you tell phenytoin from valproate in a seizure drug adverse-effect question?
The best way to distinguish them is by the signature adverse effects. Phenytoin is linked to gingival hyperplasia and hirsutism, which strongly point to it over valproate. Valproate can cause weight gain, menstrual issues, thrombocytopenia, hyperammonemia, pancreatitis, hepatotoxicity, and neural tube defects, but the stem’s combination of gingival hypertrophy plus increased facial hair is much more characteristic of phenytoin.
What is the mechanism of action of phenytoin?
Phenytoin works by blocking voltage-gated sodium channels and prolonging their inactivated state. This reduces high-frequency neuronal firing, which is why it is used for focal seizures and generalized tonic-clonic seizures. Its mechanism is similar to carbamazepine in terms of sodium-channel blockade, but the adverse-effect profile in a question stem is often what separates the two drugs.
Why is phenytoin a favorite for USMLE pharmacokinetics questions?
Phenytoin is high-yield for pharmacokinetics because it has saturable metabolism and shows zero-order kinetics at higher doses. That means small dose increases can lead to disproportionate rises in drug levels. It also has a narrow therapeutic index and many drug interactions, so exam questions often use phenytoin to test whether you recognize toxicity, nonlinear kinetics, and the importance of medication interactions.
When should you think carbamazepine instead of phenytoin on an exam?
Think carbamazepine when the stem emphasizes hyponatremia from SIADH or trigeminal neuralgia. Carbamazepine also blocks voltage-gated sodium channels and is used for focal and generalized tonic-clonic seizures, but it does not classically cause gingival hyperplasia or hirsutism. Its important adverse effects include agranulocytosis or aplastic anemia, hepatotoxicity, dizziness, diplopia, and teratogenic neural tube defects.